Keith T. Flaherty, MD of Mass General Brigham appointed to lead AACR

The American Association for Cancer Research (AACR) has named Keith Faherty, MD, director of clinical cancer research and the Richard Saltonstall Endowed Chair in Oncology at Mass General Cancer Center, a founding member of Mass General Brigham, as President-Elect for 2025-2026. Dr. Flaherty will take office as President-Elect on Monday, April 28, during the AACR’s Annual Business Meeting of Members at the AACR Annual Meeting 2025 in Chicago, Illinois and will assume the Presidency in April 2026 at the AACR Annual Meeting in San Diego, California.

Dr. Flaherty has been a member of the AACR since 2001, was elected as a Fellow of the AACR Academy in 2023 and served with distinction on the AACR’s Board of Directors from 2019 to 2022. He is also a professor of medicine at Harvard Medical School and an associate member of the Broad Institute of MIT and Harvard.

“It is the singular greatest honor of my career to be elected to serve the AACR and its membership in this capacity,” said Dr. Flaherty. “During my tenure, I hope to redouble our efforts to bridge cutting-edge discovery science with clinical translation by virtue of career development and mentorship of the next generation of translational investigators, particularly those aiming to address the needs of underserved populations.”

Dr. Flaherty has played a critical role in shaping the AACR Annual Meetings by serving as chair (2023-2024), vice chair (2020-2021), and cochair (2012-2013, 2010) of the Annual Meeting Program Committee. He was a member of the Annual Meeting Clinical Trials Committee (2018-2020, 2016-2018, 2012-2013) and chair of the Clinical Trials and Clinical Pharmacology Section of the Annual Meeting Scientific Program Committee (2013).